260 related articles for article (PubMed ID: 33136178)
41. Paraneoplastic neurological syndromes associated with non-Hodgkin lymphoma: a case series.
Dinoto A; Cheli M; Catalan M; Olivo S; Scali I; Bertolotti C; Sartori A; Manganotti P
Neurol Sci; 2022 Mar; 43(3):2077-2079. PubMed ID: 35000013
[TBL] [Abstract][Full Text] [Related]
42. Clinical approach to diagnosis of paraneoplastic neurologic syndromes.
Graus F
Handb Clin Neurol; 2024; 200():79-96. PubMed ID: 38494298
[TBL] [Abstract][Full Text] [Related]
43. Onconeural antibodies in patients with neurological symptoms: detection and clinical significance.
Raspotnig M; Vedeler CA; Storstein A
Acta Neurol Scand Suppl; 2011; (191):83-8. PubMed ID: 21711262
[TBL] [Abstract][Full Text] [Related]
44. Recommended diagnostic criteria for paraneoplastic neurological syndromes.
Graus F; Delattre JY; Antoine JC; Dalmau J; Giometto B; Grisold W; Honnorat J; Smitt PS; Vedeler Ch; Verschuuren JJ; Vincent A; Voltz R
J Neurol Neurosurg Psychiatry; 2004 Aug; 75(8):1135-40. PubMed ID: 15258215
[TBL] [Abstract][Full Text] [Related]
45. Therapeutic efficacy and safety of a human fusion construct targeting the TWEAK receptor Fn14 and containing a modified granzyme B.
Alvarez de Cienfuegos A; Cheung LH; Mohamedali KA; Whitsett TG; Winkles JA; Hittelman WN; Rosenblum MG
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32958685
[TBL] [Abstract][Full Text] [Related]
46. [Lung cancer and paraneoplastic syndromes].
Jurado Gámez B; García de Lucas MD; Gudín Rodríguez M
An Med Interna; 2001 Aug; 18(8):440-6. PubMed ID: 11589085
[TBL] [Abstract][Full Text] [Related]
47. Paraneoplastic neurological syndromes (PNS) caused by occult breast cancer and metastatic carcinoma of the lymph node.
Gong J; Zhang Y; Huang Y; Yin W; Zhang W; Feng J; Wang S; Wu X
Eur J Gynaecol Oncol; 2015; 36(4):485-7. PubMed ID: 26390710
[TBL] [Abstract][Full Text] [Related]
48. [Paraneoplastic Neurologic Syndromes].
Tanaka K
Brain Nerve; 2023 Jun; 75(6):755-762. PubMed ID: 37287359
[TBL] [Abstract][Full Text] [Related]
49. [(18)F-FDG PET/CT in the evaluation of patients suspected of paraneoplastic neurological syndrome].
García Vicente AM; Vega Caicedo CH; Mondéjar Solís R; de Ayala Fernández JÁ; Garrido Robles JA; Pena Pardo FJ; Muñoz Pasadas M; Del Saz Saucedo P; Jiménez Londoño GA; León Martín A; Soriano Castrejón Á
Rev Esp Med Nucl Imagen Mol; 2015; 34(4):236-43. PubMed ID: 25864422
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of the Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes in China.
Cai MT; Qiao S; Lai QL; Zheng Y; Yang F; Fang GL; Shen CH; Zhang YX; Ding MP
Front Immunol; 2022; 13():790400. PubMed ID: 35173717
[TBL] [Abstract][Full Text] [Related]
51. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes.
Younes-Mhenni S; Janier MF; Cinotti L; Antoine JC; Tronc F; Cottin V; Ternamian PJ; Trouillas P; Honnorat J
Brain; 2004 Oct; 127(Pt 10):2331-8. PubMed ID: 15361417
[TBL] [Abstract][Full Text] [Related]
52. The use of eye-movement recording in patients with anti-Hu antibody-associated paraneoplastic neurological syndromes to objectively determine extent and course of disease.
Janssen M; van Broekhoven F; Sillevis Smitt P; Frens M; van der Geest J
Eur J Neurol; 2021 Jun; 28(6):2126-2132. PubMed ID: 33675135
[TBL] [Abstract][Full Text] [Related]
53. Different Genetic Signatures of Small-Cell Lung Cancer Characterize Anti-GABA
Vogrig A; Pegat A; Villagrán-García M; Wucher V; Attignon V; Sohier E; Brevet M; Rogemond V; Pinto AL; Muñiz-Castrillo S; Peter E; Robert M; Picard G; Hopes L; Psimaras D; Terra A; Perrin C; Cogne D; Tabone-Eglinger S; Martinez S; Jury D; Valantin J; Gadot N; Auclair-Perrossier J; Viari A; Dubois B; Desestret V; Honnorat J
Ann Neurol; 2023 Dec; 94(6):1102-1115. PubMed ID: 37638563
[TBL] [Abstract][Full Text] [Related]
54. Accuracy of FDG-PET/CT and paraneoplastic antibodies in diagnosing cancer in paraneoplastic neurological syndromes.
Vatankulu B; Yilmaz Aksoy S; Asa S; Sager S; Sayman HB; Halac M; Sonmezoglu K
Rev Esp Med Nucl Imagen Mol; 2016; 35(1):17-21. PubMed ID: 26260889
[TBL] [Abstract][Full Text] [Related]
55. A large screen for paraneoplastic neurological autoantibodies; diagnosis and predictive values.
Seluk L; Taliansky A; Yonath H; Gilburd B; Amital H; Shoenfeld Y; Kivity S
Clin Immunol; 2019 Feb; 199():29-36. PubMed ID: 30543927
[TBL] [Abstract][Full Text] [Related]
56. Granzyme B ELISPOT assay determines the cytotoxic T lymphocyte precursor frequency after HLA-identical living-related kidney transplantation.
Gerrits JH; van de Wetering J; Ijzermans JN; Weimar W; van Besouw NM
Transplant Proc; 2005 Mar; 37(2):752-4. PubMed ID: 15848521
[TBL] [Abstract][Full Text] [Related]
57. Functional expression of granzyme B in human plasmacytoid dendritic cells: a role in allergic inflammation.
Bratke K; Nielsen J; Manig F; Klein C; Kuepper M; Geyer S; Julius P; Lommatzsch M; Virchow JC
Clin Exp Allergy; 2010 Jul; 40(7):1015-24. PubMed ID: 20412137
[TBL] [Abstract][Full Text] [Related]
58. Increased proteinase inhibitor-9 (PI-9) and reduced granzyme B in lung cancer: mechanism for immune evasion?
Soriano C; Mukaro V; Hodge G; Ahern J; Holmes M; Jersmann H; Moffat D; Meredith D; Jurisevic C; Reynolds PN; Hodge S
Lung Cancer; 2012 Jul; 77(1):38-45. PubMed ID: 22387007
[TBL] [Abstract][Full Text] [Related]
59. [Pathogenesis of paraneoplastic neurological syndromes].
Tanaka K
Brain Nerve; 2010 Apr; 62(4):309-18. PubMed ID: 20420170
[TBL] [Abstract][Full Text] [Related]
60. Increased circulating granzyme B in type 2 diabetes patients with low-grade systemic inflammation.
Cimini FA; D'Eliseo D; Barchetta I; Bertoccini L; Velotti F; Cavallo MG
Cytokine; 2019 Mar; 115():104-108. PubMed ID: 30473178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
